Cargando…
Quantification of (11)C-PIB kinetics in cardiac amyloidosis
BACKGROUND: The purpose of this work was to determine the optimal tracer kinetic model of (11)C-PIB and to validate the use of the simplified methods retention index (RI) and standardized uptake value (SUV) for quantification of cardiac (11)C-PIB uptake in amyloidosis. METHODS AND RESULTS: Single-ti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326793/ https://www.ncbi.nlm.nih.gov/pubmed/30039218 http://dx.doi.org/10.1007/s12350-018-1349-x |
_version_ | 1783552411545108480 |
---|---|
author | Kero, Tanja Sörensen, Jens Antoni, Gunnar Wilking, Helena Carlson, Kristina Vedin, Ola Rosengren, Sara Wikström, Gerhard Lubberink, Mark |
author_facet | Kero, Tanja Sörensen, Jens Antoni, Gunnar Wilking, Helena Carlson, Kristina Vedin, Ola Rosengren, Sara Wikström, Gerhard Lubberink, Mark |
author_sort | Kero, Tanja |
collection | PubMed |
description | BACKGROUND: The purpose of this work was to determine the optimal tracer kinetic model of (11)C-PIB and to validate the use of the simplified methods retention index (RI) and standardized uptake value (SUV) for quantification of cardiac (11)C-PIB uptake in amyloidosis. METHODS AND RESULTS: Single-tissue, reversible and irreversible two-tissue models were fitted to data from seven cardiac amyloidosis patients who underwent (11)C-PIB PET scans and arterial blood sampling for measurement of blood radioactivity and metabolites. The irreversible two-tissue model (2Tirr) best described cardiac (11)C-PIB uptake. RI and SUV showed high correlation with the rate of irreversible binding (K(i)) from the 2Tirr model (r(2 )=0.95 and r(2 )=0.94). Retrospective data from 10 amyloidosis patients and 5 healthy controls were analyzed using RI, SUV, as well as compartment modelling with a population-average metabolite correction. All measures were higher in amyloidosis patients than in healthy controls (p=.001), but with an overlap between groups for K(i). CONCLUSION: An irreversible two-tissue model best describes the (11)C-PIB uptake in cardiac amyloidosis. RI and SUV correlate well with K(i) from the 2Tirr model. RI and SUV discriminate better between amyloidosis patients and controls than K(i) based on population-average metabolite correction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12350-018-1349-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7326793 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-73267932020-07-07 Quantification of (11)C-PIB kinetics in cardiac amyloidosis Kero, Tanja Sörensen, Jens Antoni, Gunnar Wilking, Helena Carlson, Kristina Vedin, Ola Rosengren, Sara Wikström, Gerhard Lubberink, Mark J Nucl Cardiol Original Article BACKGROUND: The purpose of this work was to determine the optimal tracer kinetic model of (11)C-PIB and to validate the use of the simplified methods retention index (RI) and standardized uptake value (SUV) for quantification of cardiac (11)C-PIB uptake in amyloidosis. METHODS AND RESULTS: Single-tissue, reversible and irreversible two-tissue models were fitted to data from seven cardiac amyloidosis patients who underwent (11)C-PIB PET scans and arterial blood sampling for measurement of blood radioactivity and metabolites. The irreversible two-tissue model (2Tirr) best described cardiac (11)C-PIB uptake. RI and SUV showed high correlation with the rate of irreversible binding (K(i)) from the 2Tirr model (r(2 )=0.95 and r(2 )=0.94). Retrospective data from 10 amyloidosis patients and 5 healthy controls were analyzed using RI, SUV, as well as compartment modelling with a population-average metabolite correction. All measures were higher in amyloidosis patients than in healthy controls (p=.001), but with an overlap between groups for K(i). CONCLUSION: An irreversible two-tissue model best describes the (11)C-PIB uptake in cardiac amyloidosis. RI and SUV correlate well with K(i) from the 2Tirr model. RI and SUV discriminate better between amyloidosis patients and controls than K(i) based on population-average metabolite correction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12350-018-1349-x) contains supplementary material, which is available to authorized users. Springer International Publishing 2018-07-23 2020 /pmc/articles/PMC7326793/ /pubmed/30039218 http://dx.doi.org/10.1007/s12350-018-1349-x Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Kero, Tanja Sörensen, Jens Antoni, Gunnar Wilking, Helena Carlson, Kristina Vedin, Ola Rosengren, Sara Wikström, Gerhard Lubberink, Mark Quantification of (11)C-PIB kinetics in cardiac amyloidosis |
title | Quantification of (11)C-PIB kinetics in cardiac amyloidosis |
title_full | Quantification of (11)C-PIB kinetics in cardiac amyloidosis |
title_fullStr | Quantification of (11)C-PIB kinetics in cardiac amyloidosis |
title_full_unstemmed | Quantification of (11)C-PIB kinetics in cardiac amyloidosis |
title_short | Quantification of (11)C-PIB kinetics in cardiac amyloidosis |
title_sort | quantification of (11)c-pib kinetics in cardiac amyloidosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326793/ https://www.ncbi.nlm.nih.gov/pubmed/30039218 http://dx.doi.org/10.1007/s12350-018-1349-x |
work_keys_str_mv | AT kerotanja quantificationof11cpibkineticsincardiacamyloidosis AT sorensenjens quantificationof11cpibkineticsincardiacamyloidosis AT antonigunnar quantificationof11cpibkineticsincardiacamyloidosis AT wilkinghelena quantificationof11cpibkineticsincardiacamyloidosis AT carlsonkristina quantificationof11cpibkineticsincardiacamyloidosis AT vedinola quantificationof11cpibkineticsincardiacamyloidosis AT rosengrensara quantificationof11cpibkineticsincardiacamyloidosis AT wikstromgerhard quantificationof11cpibkineticsincardiacamyloidosis AT lubberinkmark quantificationof11cpibkineticsincardiacamyloidosis |